Reuters logo
BRIEF-BioCryst reports additional positive results from second interim analysis of APEX-1 trial
May 25, 2017 / 12:18 PM / 6 months ago

BRIEF-BioCryst reports additional positive results from second interim analysis of APEX-1 trial

May 25 (Reuters) - BioCryst Pharmaceuticals Inc

* BioCryst reports additional positive results from the second interim analysis of its APEX-1 trial

* BioCryst Pharma - a pre-planned analysis of peripheral and abdominal attacks showed reductions in peripheral attacks of 74%, 54%, 90% compared with placebo

* BioCryst Pharmaceuticals Inc says oral BCX7353 once-daily for 28 days was generally safe and well tolerated in subjects with hae

* BioCryst Pharmaceuticals Inc says additionally, no significant laboratory abnormalities were observed in two lower dose groups

* BioCryst Pharmaceuticals Inc - there were no serious aes and no severe aes in APEX-1 trial

* BioCryst Pharmaceuticals - three subjects in bcx7353 350 mg treatment arm, two of which were previously reported, discontinued study drug before day 28

* BioCryst Pharmaceuticals Inc says most common treatment-emergent adverse events were common cold and diarrhea in trial Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below